265 related articles for article (PubMed ID: 33598432)
1. Propranolol Sensitizes Vascular Sarcoma Cells to Doxorubicin by Altering Lysosomal Drug Sequestration and Drug Efflux.
Saha J; Kim JH; Amaya CN; Witcher C; Khammanivong A; Korpela DM; Brown DR; Taylor J; Bryan BA; Dickerson EB
Front Oncol; 2020; 10():614288. PubMed ID: 33598432
[TBL] [Abstract][Full Text] [Related]
2. The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study.
Porcelli L; Garofoli M; Di Fonte R; Fucci L; Volpicella M; Strippoli S; Guida M; Azzariti A
Sci Rep; 2020 Jun; 10(1):10465. PubMed ID: 32591592
[TBL] [Abstract][Full Text] [Related]
3. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study.
Pasquier E; André N; Street J; Chougule A; Rekhi B; Ghosh J; Philip DSJ; Meurer M; MacKenzie KL; Kavallaris M; Banavali SD
EBioMedicine; 2016 Apr; 6():87-95. PubMed ID: 27211551
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression.
Gorden BH; Saha J; Khammanivong A; Schwartz GK; Dickerson EB
Vasc Cell; 2014; 6():20. PubMed ID: 25295160
[TBL] [Abstract][Full Text] [Related]
5. Lysosomes as mediators of drug resistance in cancer.
Zhitomirsky B; Assaraf YG
Drug Resist Updat; 2016 Jan; 24():23-33. PubMed ID: 26830313
[TBL] [Abstract][Full Text] [Related]
6. The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells.
Duckett MM; Phung SK; Nguyen L; Khammanivong A; Dickerson E; Dusenbery K; Lawrence J
Vet Comp Oncol; 2020 Mar; 18(1):128-140. PubMed ID: 31778284
[TBL] [Abstract][Full Text] [Related]
7. High drug efflux pump capacity and low DNA damage response induce doxorubicin resistance in canine hemangiosarcoma cell lines.
Morita A; Aoshima K; Gulay KCM; Onishi S; Shibata Y; Yasui H; Kobayashi A; Kimura T
Res Vet Sci; 2019 Dec; 127():1-10. PubMed ID: 31648115
[TBL] [Abstract][Full Text] [Related]
8. Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter.
Seebacher NA; Lane DJ; Jansson PJ; Richardson DR
J Biol Chem; 2016 Feb; 291(8):3796-820. PubMed ID: 26601947
[TBL] [Abstract][Full Text] [Related]
9. Activity of Lysosomal ABCC3, ABCC5 and ABCC10 is Responsible for Lysosomal Sequestration of Doxorubicin and Paclitaxel-Oregongreen488 in Paclitaxel-Resistant Cancer Cell Lines.
Gronkowska K; Michlewska S; Robaszkiewicz A
Cell Physiol Biochem; 2023 Sep; 57(5):360-378. PubMed ID: 37767694
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis.
Zhitomirsky B; Assaraf YG
Oncotarget; 2017 Jul; 8(28):45117-45132. PubMed ID: 28187461
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.
Ouar Z; Bens M; Vignes C; Paulais M; Pringel C; Fleury J; Cluzeaud F; Lacave R; Vandewalle A
Biochem J; 2003 Feb; 370(Pt 1):185-93. PubMed ID: 12435274
[TBL] [Abstract][Full Text] [Related]
12. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells.
Wang E; Lee MD; Dunn KW
J Cell Physiol; 2000 Aug; 184(2):263-74. PubMed ID: 10867652
[TBL] [Abstract][Full Text] [Related]
13. Differences in the Antinociceptive Effects and Binding Properties of Propranolol and Bupranolol Enantiomers.
Martin LJ; Piltonen MH; Gauthier J; Convertino M; Acland EL; Dokholyan NV; Mogil JS; Diatchenko L; Maixner W
J Pain; 2015 Dec; 16(12):1321-1333. PubMed ID: 26456674
[TBL] [Abstract][Full Text] [Related]
14. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.
Hurwitz SJ; Terashima M; Mizunuma N; Slapak CA
Blood; 1997 May; 89(10):3745-54. PubMed ID: 9160680
[TBL] [Abstract][Full Text] [Related]
15. Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.
Al-Akra L; Bae DH; Sahni S; Huang MLH; Park KC; Lane DJR; Jansson PJ; Richardson DR
J Biol Chem; 2018 Mar; 293(10):3562-3587. PubMed ID: 29305422
[TBL] [Abstract][Full Text] [Related]
16. PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study.
Heinhuis KM; IJzerman NS; Koenen AM; van der Graaf WTA; Haas RL; Beijnen JH; Huitema ADR; van Houdt WJ; Steeghs N
BMJ Open; 2020 Sep; 10(9):e039449. PubMed ID: 32912994
[TBL] [Abstract][Full Text] [Related]
17. Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma.
Amaya CN; Perkins M; Belmont A; Herrera C; Nasrazadani A; Vargas A; Khayou T; Montoya A; Ballou Y; Galvan D; Rivas A; Rains S; Patel L; Ortega V; Lopez C; Chow W; Dickerson EB; Bryan BA
Oncoscience; 2018 Mar; 5(3-4):109-119. PubMed ID: 29854879
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
19. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).
Jansson PJ; Yamagishi T; Arvind A; Seebacher N; Gutierrez E; Stacy A; Maleki S; Sharp D; Sahni S; Richardson DR
J Biol Chem; 2015 Apr; 290(15):9588-603. PubMed ID: 25720491
[TBL] [Abstract][Full Text] [Related]
20. Influence of lysosomal sequestration on multidrug resistance in cancer cells.
Halaby R
Cancer Drug Resist; 2019; 2(1):31-42. PubMed ID: 35582144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
